In today’s highlights in the medical world, Pennsylvania state senator Doug Mastriano has initiated a proposal for an over-the-counter availability of ivermectin, a medication approved by the FDA for treating parasitic infections such as scabies and river blindness. Despite this move, which echoes similar laws passed in Idaho, Arkansas, and Tennessee, ivermectin is currently not FDA-approved for COVID-19 treatment. Advocates of over-the-counter accessibility believe this could benefit patients, particularly those in remote locations. However, medical professionals caution the potential dangers of misuse and emphasize the necessity for medical supervision.
In a more tuned-in perspective to our Infection Preventionist readers, a significant recommendation from the Society for Healthcare Epidemiology of America (SHEA), in their latest multisociety position paper, calls for pressing enhancements in infection prevention and control (IPC) strategies within U.S health care facilities. The group pleads for hospitals and regulators to see IPC as an integral part of patient safety and operational sturdiness, rather than merely regulatory conformity. This includes robust leadership structures, better staffing, and direct executive backing – lessons learnt from COVID-19 pandemic shortcomings.
In the realm of innovation, researchers at Karolinska Institutet are exploring AI-driven biomarkers derived from urine tests for early detection and severity assessment of prostate cancer. This non-invasive procedure, if validated in ongoing clinical trials, could bring about revolutionary changes in future prostate cancer diagnosis methods.
Moving towards other health matters, recent innings of the ACP Internal Medicine Meeting 2025 underlined that female cancer survivors are more prone to fatigue and depression, while other discussions were centered on how Rhode Island plans to salvage primary care.
In finance-related briefings, valuable insights were given in the Morning Medical Update Episode 62 on how to avoid physician financial mistakes with The White Coat Investor.
Additionally, the Myomo makes strides with the launch of MyoPro 2x aimed at improving independence for individuals with arm and hand paralysis. Lastly, FDA valve-teasing with a pending verdict on Novavax’s COVID-19 booster warrants further monitoring from the healthcare community.